APPENDICES. A systematic review and economic model of the ...

More documents

Recommendations

Info

158 Appendix 1 Search strategy for methylphenidate: 1999–2004 #1 113 45 1. or methylphenidate or equasym or centedrin or phenidylate or Ritalin or tsentedrin or alpha phenyl alpha 2 piperidly acetic acid methyl ester or alpha phenyl 2 piperidineacetic acid methyl ester or c 4311 b or c4311 b or c4311b centedrin or concerta or d erythro methyl phenidylacetate or d1 erythro methyl phenidylacetate or metadate or methylfenidate or methyl phenidate or methylphenidylacetate or methylphenindate or methylphenydate or methyl 2 phenyl 2 piperid 2 ylacetate or phenidylate or phenidyl hydrochloride or .sr 20 or attenta or methylin or ritaline or riphenidate or ritalina or ritaline or rubifen or tranquilyn #2 Behavio* symptom* and hyperactiv* #3 Cognition* and hyperactiv* #4 attention deficit* or minimal brain damage* or .minimal brain dysfunction* or hyperkinetic or adhd or ad hd or addh or hkd or impulsivity or inattent* #5 #2 or #3 or #4 #6 #1 and #5 This retrieved 678 records in SCI and 398 in SSCI. CENTRAL (2004: Issue 2) Searched: 12 July 2004 at http://www.nelh.nhs.uk/cochrane.asp Search strategy for atomoxetine: #1 BEHAVIORAL SYMPTOMS explode all trees (MeSH) #2 hyperactiv* #3 COGNITION DISORDERS explode all trees (MeSH) #4 (#1 and #2) #5 (#3 and #2) #6 ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY single term (MeSH) #7 (attention next deficit*) #8 (#6 or #7) #9 (#4 or #5) #10 (#8 or #9) #11 (minimal next brain next damage*) #12 (minimal next brain next dysfunction*) #13 hyperkinetic* #14 addh #15 (ad next hd) #16 hkd #17 inattent* #18 impulsivity #19 adhd #20 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19) #21 tomoxetine #22 (n next methyl next gamma next methylphenoxy next phenylpropylamine) #23 (n next methyl next methylphenoxy next phenylpropylamine) #24 (n next methyl next phenyl next ortho next tolyloxy next propylamine) #25 strattera #26 atomoxetine #27 (#21 or #22 or #23 or #24 or #25 or #26) #28 (#27 and #20) ( 1981 to current date ) This retrieved 17 records. CENTRAL (2004: Issue 2) Searched: 12 July 2004 at http://www.nelh.nhs.uk/cochrane.asp Search strategy for dexamfetamine: #1 BEHAVIORAL SYMPTOMS explode all trees (MeSH) #2 hyperactiv* #3 COGNITION DISORDERS explode all trees (MeSH) #4 (#1 and #2) #5 (#3 and #2) #6 ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY single term (MeSH) #7 (attention next deficit*) #8 (#6 or #7) #9 (#4 or #5) #10 (#8 or #9) #11 (minimal next brain next damage*) #12 (minimal next brain next dysfunction*) #13 hyperkinetic* #14 addh #15 (ad next hd) #16 hkd #17 inattent* #18 impulsivity #19 adhd #20 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19) #21 DEXTROAMPHETAMINE single term (MeSH) #22 (dephadren or dexadrine or dexaline or dexalme or dexalone or dexamed or dexamphetamin or dexamphethamine or dexamphoid or dexamyl or (dexaspan next b) or dexeamphetanine or dexoval or dextrostat or diocarb or diocurb or domafate or domefate or doxedrine or (d next phenyl
next aminopropane) or dynaphenyl or evrodex or hetamine or obesedrin or obesonil or phetadex or (simpamina next d) or sympamin) #23 (dexamphetamine or dexamfetamine or (d next amphetamine) or dexedrine or dextroamphetamine or (dextro next amphetamine) or afatin or afettine or albemap or amfetasul or amitrene or amphedrine or amphex or amsustain or ardex or betafedrina or (betaphedrine next biphetamine next carboxyphen next dadex) or methylphenethylamin or (d next alpha next methylphenethylamine next sulfate) or (d next amphetamine) or daprisal or (d next beta next phenylisopropylamine)) #24 (#21 or #22 or #23) #25 (#20 and #24) (1997 to current date ) This retrieved 33 records. CENTRAL (2004: Issue 2) Searched: 12 July 2004 at http://www.nelh.nhs.uk/cochrane.asp Search strategy for methylphenidate: #1 BEHAVIORAL SYMPTOMS explode all trees (MeSH) #2 hyperactiv* #3 COGNITION DISORDERS explode all trees (MeSH) #4 (#1 and #2) #5 (#3 and #2) #6 ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY single term (MeSH) #7 (attention next deficit*) #8 (#6 or #7) #9 (#4 or #5) #10 (#8 or #9) #11 (minimal next brain next damage*) #12 (minimal next brain next dysfunction*) #13 hyperkinetic* #14 addh #15 (ad next hd) #16 hkd #17 inattent* #18 impulsivity #19 adhd #20 (#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19) #21 (methylphenidate or equasym or centedrin or phenidylate or ritalin or tsentedrin or (alpha next phenyl next alpha next piperidly next acetic next acid next methyl next ester) or (alpha next phenyl next piperidineacetic next acid next methyl next ester) or centedrin or © Queen’s Printer and Controller of HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 23 concerta or (d next erythro next methyl next phenidylacetate) or (d1 next erythro next methyl next phenidylacetate) or metadate or methylfenidate or (methyl next phenidate) or methylphenidylacetate or methylphenindate or methylphenydate or (methyl next phenyl next piperid next ylacetate) or phenidylate or (phenidyl next hydrochloride) or attenta or methylin or ritaline or riphenidate or ritalina or ritaline or rubifen or tranquilyn) #22 METHYLPHENIDATE single term (MeSH) #23 (#21 or #22) #24 (#20 and #23) (1999 to current date ) This retrieved 115 records. Searches for ongoing and recently completed research The following databases were searched for papers relating to ADHD and an initial sift for relevance was carried out by the information officer. Controlled Clinical Trials Searched: 19 July 2004 at http://www.controlledtrials.com/ ClinicalTrials.gov Searched: 19 July 2004 at http://www.clinicaltrials.gov/ ReFeR database Searched: 19 July 2004 at http://http://www.info.doh.gov.uk/doh/refr–web.nsf/ Home?OpenForm The following search terms were used in these databases; hyperactivity attention deficit minimal brain damage minimal brain dysfunction hyperkinetic adhd ad hd addh hkd impulsivity inattentive National Research Register (NRR) (2004: Issue 2) Searched: 12 July 2004 at http://www.nrr.nhs.uk/search.htm #1 BEHAVIORAL SYMPTOMS explode all trees (MeSH) #2 hyperactiv* 159
Page 1 and 2: Appendices A systematic review and
Page 3 and 4: Clinical effectiveness information
Page 5 and 6: Searches for systematic reviews in
Page 7 and 8: 19. methyl phenidate.mp. 20. methyl
Page 9 and 10: 43. attention deficit$.mp. 44. 42 o
Page 11 and 12: MEDLINE in-process and other non-in
Page 13: PsycINFO (1967-July 2004) Searched:
Page 17 and 18: or ritaline or riphenidate or rital
Page 19: System for Information on Grey Lite
Page 22 and 23: 166 Appendix 2 S hyperkinetic S imp
Page 24 and 25: 168 Appendix 2 19. (eq5d or eq 5d o
Page 26 and 27: 170 Appendix 2 14. (person trade of
Page 28 and 29: 172 Appendix 3 Reference Reason for
Page 31: Appendix 4 © Queen’s Printer and
Page 34 and 35: 178 Appendix 5 8. Was the statistic
Page 36 and 37: 180 Appendix 6 Cost-effectiveness R
Page 38 and 39: 182 Appendix 7 Appropriateness of m
Page 40 and 41: 184 Appendix 7 Sensitivity analysis
Page 42 and 43: 186 Appendix 7 Sensitivity analysis
Page 44 and 45: 188 Appendix 8 Probability cost-eff
Page 47 and 48: Appendix 10 © Queen’s Printer an
Page 49 and 50: Health state Responder to ATX, no s
Page 51 and 52: Health state Responder to IR-MPH, R
Page 53 and 54: Health state Responder to ER-MPH, R
Page 55: #Baseline shift random effects mode
Page 58 and 59: 202 Appendix 12 Study Intervention
Page 60 and 61: 204 Appendix 12 Study Intervention
Page 62 and 63: 206 Appendix 12 Core symptoms Educa
Page 64 and 65:
208 Appendix 12 Core symptoms Educa
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
216 Appendix 12 Study Intervention
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222:
366 Appendix 13 Study characteristi
show all

APPENDICES. A systematic review and economic model of the ...

Create successful ePaper yourself

Delete template?

Save as template?